GLP-1 Market
LLY $1281.91 ▲ +0.2% NVO $38.67 ▼ -1.2% PFE $29.80 ▲ +0.0% VKTX $24.89 ▲ +2.8% KLRA $13.13 ▲ +2.8% GPCR $21.55 ▲ +2.1% RHHBY $60.37 ▲ +0.7%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Protandim

Company
Duke University
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Oct 28, 2026

Trial details
  • Completed NCT NCT00936000

    Antioxidant Replacement Therapy in Patients With Alcohol Abuse

    Not yet reported University of Colorado, Denver 38 participants Est. completion 2010-09 1 site
    Other conditions: Alcohol Abuse
    View official trial listing →
  • Completed NCT NCT00977730

    The Effect of Protandim on Non-alcoholic Steatohepatitis

    Not yet reported University of Colorado, Denver 70 participants Est. completion 2011-07 1 site
    Other conditions: Non-Alcoholic Steatohepatitis
    View official trial listing →
  • Withdrawn NCT NCT01125501

    Protandim and the Metabolic Syndrome

    Not yet reported SomaLogic, Inc. Est. completion 2010-06 1 site
    Metabolic syndrome
    View official trial listing →
  • Completed NCT NCT02172625

    The Effect of Protandim Supplementation on Oxidative Damage and Athletic Performance

    Not yet reported University of Louisville 40 participants Est. completion 2016-06 1 site Stand-alone
    Other conditions: Oxidative Stress
    View official trial listing →
  • Completed NCT NCT06429059

    ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments

    Not yet reported Duke University 50 participants Est. completion 2025-06-24 2 sites Stand-alone
    Other conditions: Amyotrophic Lateral Sclerosis ALS
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.